Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib

Internal Medicine Journal

Volumn 41, Issue 4, 2011, Pages 348-350

  Moore, H ^a   Romeril, K ^a  

^a WELLINGTON HOSPITAL   (New Zealand)

Author keywords

Fever; Microangiopathic haemolytic syndrome; P53 deletion; Plasma cell dyscrasia

Indexed keywords

BILIRUBIN; BORTEZOMIB; C REACTIVE PROTEIN; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; HAPTOGLOBIN; IMMUNOGLOBULIN KAPPA CHAIN; PREDNISONE; PROTEIN P53; THALIDOMIDE;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TRANSFUSION; BONE MARROW EXAMINATION; CASE REPORT; CELL INFILTRATION; CREATININE BLOOD LEVEL; ELECTROPHORESIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; LIGHT CHAIN; MULTIPLE MYELOMA; NIGHT SWEAT; PALLOR; PLASMA CELL; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINE COLOR;

ADAM PROTEINS; BORONIC ACIDS; FEMALE; FEVER OF UNKNOWN ORIGIN; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PURPURA, THROMBOTIC THROMBOCYTOPENIC; PYRAZINES;

EID: 79955040869     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02458.x     Document Type: Article

References (20)

1. Monta R, Hashino S, Shirai S, Fujita N, Onozawa R, Kahata K etal. Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma. Int J Hematol 2008; 88: 248-50.
2. Amorosi EL, Ultmann JE. TTP report of 16 cases and review of the literature. Medicine (Baltimore) 1966; 45: 139-59.
3. George JN. Clinical practice TTP. N Engl J Med 2006; 354: 1927-35.
4. George JN, Li X, McMinn JR, Terrell DR, Vesely SK, Selby GB. TTP-HUS following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion 2004; 44: 294-304.
5. Palmisano J, Agraharker M, Kaplan AA. Successful treatment of cisplatin induced HUS with therapeutic plasma exchange. Am J Kidney Dis 1998; 32: 314-7.
6. Bianchi V, Robles R, Alberio L, Furlan M, Lämmle B. von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenia disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100: 710-3.
7. Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A etal. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis induced DIC: its correlation with development of renal failure. Blood 2006; 107: 528-34.
8. Noris M, Bucchioni S, Galbusera M, Donadellli R, Bresin E, Castelletti F etal. Complement factor H mutation in familial TTP with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol 2005; 16: 1177-83.
9. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-12.
10. Zhang XG, Klein B, Bataille R. IL-6 is a potent myeloma cell growth factor in patients with aggressive Multiple Myeloma. Blood 1989; 74: 11-3.
11. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K etal. Autocrine generation and requirement of BSF2/IL6 for human multiple myelomas. Nature 1988; 332: 83-5.
12. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of IL-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84: 2008-11.
13. Mateos MV, San Miguel J. Effect of bortezomib in multiple myeloma. Best Pract Res Clin Haematol 2007; 20: 701-15.
14. Min C-K, Lee S, Kim Y-J, Eom K-S, Lee J-W, Min W-S etal. Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines. Eur J Haematol 2006; 76: 265-8.
15. Mueller PS, Terrell CL, Gertz MA. Fever of unknown origin caused by multiple myeloma. A report of 9 cases. Arch Intern Med 2002; 162: 1305-9.
16. Petersdorf RB, Beeson PB. Fever of unexplained origin: report on 100 cases. Medicine (Baltimore) 1961; 40: 1-30.
17. Drach J, Ackermann J, Fritz E, Krömer E, Schuster R, Gisslinger H etal. Presence of a p53 deletion in patients with multiple myeloma predicts for short survival after conventional dose chemotherapy. Blood 1998; 92: 802-9.
18. Chang H, Qi C, Yi Q-L, Reece D, Stewart AK. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with Multiple Myeloma following ASCT. Blood 2005; 105: 358-60.
19. Mikhael JR, Goodwin J, Qi X, Stewart K, Reece D, Chen C etal. p53 deletion detection yields high response rates but rapid progression and poor overall survival in multiple myeloma patients undergoing ASCT. ASH Annual Meeting Abstracts 2007; 110: 290-953.
20. Reece DE, Trieu Y, Chang H, Xu W, Anglin P, Chen C etal. Treatment of relapsed and refractory multiple myeloma in patients with p53 deletion. ASH Annual Meeting Abstracts 2008; 112: 607-1724.